Skip to main content
SpringerLink
Log in

Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen – wann und welcher Tracer?

Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists—when and which tracer?

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Die prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) löst zunehmend konventionelle bildgebende Verfahren zum Staging des Prostatakarzinoms ab. Herausfordernd sind ihr richtiger und stadiengerechter Einsatz sowie ihre Interpretation.

Fragestellung

Wie und wann wird die PSMA-PET in der Patientenversorgung eingesetzt, um die Therapie optimal zu steuern?

Material und Methode

Systematische Darstellung und Diskussion des aktuellen Wissenstandes, der Leitlinien und des Expertenwissens zur PSMA-PET mit Ausblick auf kommende Studien.

Schlussfolgerung

Die PSMA-PET ist der neue Standard zum systemischen Staging des Prostatakarzinoms und ermöglicht eine zielgerichtete Patientenversorgung mit neuen lokalen, oligometastatischen und systemischen Behandlungskonzepten.

Abstract

Background

Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly replacing conventional imaging for staging of prostate cancer. A major challenge is its appropriate use and correct interpretation.

Objectives

How and when is PSMA PET used in patient care to optimally direct therapy?

Materials and methods

Systematic presentation and discussion of the current state of knowledge, guidelines and expert knowledge on PSMA PET with a summary of ongoing studies.

Conclusion

PSMA PET is the new standard for systemic staging of prostate cancer, enabling precision patient care with novel local, oligometastatic, and systemic treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Aggarwal R, Wei X, Kim W et al (2018) Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 1:78–82. https://doi.org/10.1016/j.euo.2018.03.010

    Article  PubMed  Google Scholar 

  2. Amiel T, Würnschimmel C, Heck M et al (2021) Regional lymph node metastasis on prostate specific membrane antigen positron emission tomography correlates with decreased biochemical recurrence-free and therapy-free survival after radical prostatectomy: a retrospective single-center single-arm observational study. J Urol 205:1663–1670. https://doi.org/10.1097/JU.0000000000001596

    Article  PubMed  Google Scholar 

  3. Anttinen M, Ettala O, Malaspina S et al (2020) A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol. https://doi.org/10.1016/j.euo.2020.06.012

    Article  PubMed  Google Scholar 

  4. Calais J, Ceci F, Eiber M et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20:1286–1294. https://doi.org/10.1016/S1470-2045(19)30415-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Calais J, Fendler WP, Eiber M et al (2018) Impact of 68ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59:434–441. https://doi.org/10.2967/jnumed.117.202945

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ceci F, Oprea-Lager DE, Emmett L et al (2021) E‑PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 48:1626–1638. https://doi.org/10.1007/s00259-021-05245-y

    Article  PubMed  PubMed Central  Google Scholar 

  7. EAU Guidelines (2021) Prostate cancer. https://uroweb.org/guideline/prostate-cancer/. Zugegriffen: 22. Dez. 2021

  8. Eiber M, Herrmann K, Calais J et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478. https://doi.org/10.2967/jnumed.117.198119

    Article  PubMed  Google Scholar 

  9. Emmett L, Buteau J, Papa N et al (2021) The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol 80:682–689. https://doi.org/10.1016/j.eururo.2021.08.002

    Article  CAS  PubMed  Google Scholar 

  10. Emmett L, Yin C, Crumbaker M et al (2019) Rapid modulation of PSMA expression by androgen deprivation: serial 68ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60:950–954. https://doi.org/10.2967/jnumed.118.223099

    Article  CAS  PubMed  Google Scholar 

  11. Ettala O, Malaspina S, Tuokkola T et al (2020) Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging 47:665–673. https://doi.org/10.1007/s00259-019-04635-7

    Article  CAS  PubMed  Google Scholar 

  12. Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856–863. https://doi.org/10.1001/jamaoncol.2019.0096

    Article  PubMed  PubMed Central  Google Scholar 

  13. Fendler WP, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014–1024. https://doi.org/10.1007/s00259-017-3670-z

    Article  PubMed  Google Scholar 

  14. Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448–7454. https://doi.org/10.1158/1078-0432.CCR-19-1050

    Article  CAS  PubMed  Google Scholar 

  15. Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588

    Article  PubMed  Google Scholar 

  16. Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74:179–190. https://doi.org/10.1016/j.eururo.2018.03.030

    Article  CAS  PubMed  Google Scholar 

  17. Hoberück S, Löck S, Borkowetz A et al (2021) Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res 11:109. https://doi.org/10.1186/s13550-021-00845-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hofman MS, Emmett L, Sandhu S et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797–804. https://doi.org/10.1016/S0140-6736(21)00237-3

    Article  CAS  PubMed  Google Scholar 

  19. Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7

    Article  CAS  PubMed  Google Scholar 

  20. Jadvar H, Calais J, Fanti S et al (2021) Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. https://doi.org/10.2967/jnumed.121.263262

    Article  PubMed  Google Scholar 

  21. Kroenke M, Mirzoyan L, Horn T et al (2021) Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA‑7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity. J Nucl Med 62:1082–1088. https://doi.org/10.2967/jnumed.120.251447

    Article  CAS  PubMed  Google Scholar 

  22. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2021) S3-Leitlinie Prostatakarzinom, Langversion 6.2. https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 23. Dez. 2021 (AWMF Registernummer:043/022OL)

  23. Morris MJ, Rowe SP, Gorin MA et al (2021) Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 27:3674–3682. https://doi.org/10.1158/1078-0432.CCR-20-4573

    Article  CAS  PubMed  Google Scholar 

  24. Mullins JK, Feng Z, Trock BJ et al (2012) The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 188:2219–2224. https://doi.org/10.1016/j.juro.2012.08.028

    Article  PubMed  Google Scholar 

  25. Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650–659. https://doi.org/10.1001/jamaoncol.2020.0147

    Article  PubMed  PubMed Central  Google Scholar 

  26. Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65:965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029

    Article  PubMed  Google Scholar 

  27. Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091–1103. https://doi.org/10.1056/NEJMoa2107322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schaeffer E, Srinivas S, Antonarakis ES et al (2021) NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Canc Netw 19:134–143. https://doi.org/10.6004/jnccn.2021.0008

    Article  CAS  PubMed  Google Scholar 

  29. Sonni I, Eiber M, Fendler WP et al (2020) Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med 61:1153–1160. https://doi.org/10.2967/jnumed.119.237602

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

    Article  PubMed  Google Scholar 

  31. Valle LF, Lehrer EJ, Markovic D et al (2020) A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. https://doi.org/10.1016/j.eururo.2020.11.010

    Article  PubMed  Google Scholar 

  32. Vaz S, Hadaschik B, Gabriel M et al (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9–15. https://doi.org/10.1007/s00259-019-04529-8

    Article  CAS  PubMed  Google Scholar 

  33. Xiang M, Ma TM, Savjani R et al (2021) Performance of a prostate-specific membrane antigen positron emission tomography/computed tomography-derived risk-stratification tool for high-risk and very high-risk prostate cancer. JAMA Netw Open 4:e2138550. https://doi.org/10.1001/jamanetworkopen.2021.38550

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland

    Christoph Berliner MD & Wolfgang P. Fendler MD

  2. Martini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    Tobias Maurer MD

  3. Klinik für Urologie, Universitätsklinikum Essen, Essen, Deutschland

    Claudia Kesch MD

  4. Klinik für Nuklearmedizin, Klinikum Rechts , der Isar, Technische Universität München, München, Deutschland

    Matthias Eiber MD

  5. Klinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    Tobias Maurer MD

Authors
  1. Christoph Berliner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Kesch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang P. Fendler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthias Eiber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tobias Maurer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Berliner MD.

Ethics declarations

Interessenkonflikt

C. Berliner erhielt Zahlungen von Janssen Pharma (Vorträge) und ABX (Bildinterpretation) außerhalb der veröffentlichten Arbeit. C. Kesch erhält Zahlungen von Advanced Accelerator Applications (Drittmittelförderungen) außerhalb dieser Arbeit. W.P. Fendler erhielt Zahlungen von SOFIE Bioscience (Drittmittelförderung), Janssen (Beratungs‑, Vortragshonorar), Calyx (Beratungshonorar), Bayer (Beratungs‑, Vortragshonorar), und Parexel (Bildinterpretation) außerhalb dieser Arbeit. M. Eiber hält Teile des Patents für rhPSMA und erhielt Zahlungen von Dritmittelförderung von Blue Earth Diagnostics sowie Beratungshonorare von Blue Earth Diagnostics, Novartis, Telix, Bayer, Point Biopharma und Janssen außerhalb dieser Arbeit. T. Maurer ist/war Berater für Advanced Applications S.A., Astellas, Axiom, Blue Earth Diagnostics, GEMoAb, Novartis, ROTOP Pharma, Telix, sowie erhielt Vortragshonorar von Astellas, Bayer, Sanofi-Aventis und Phillips außerhalb dieser Arbeit.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berliner, C., Kesch, C., Fendler, W.P. et al. Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen – wann und welcher Tracer?. Urologe 61, 384–391 (2022). https://doi.org/10.1007/s00120-022-01766-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-022-01766-y

Schlüsselwörter

Keywords

Search

Navigation